Patents by Inventor Jodi Craigo
Jodi Craigo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240398947Abstract: Compositions, methods, and kits that can be used to treat cancer are described herein. For example, pharmaceutical compositions containing beraprost or salts thereof can be used as an adjuvant therapy with chimeric antigen receptor T-cells (CAR T-cells) to treat cancer while reducing or eliminating undesired and potentially dangerous cytokine release syndrome (CRS) effects.Type: ApplicationFiled: May 31, 2024Publication date: December 5, 2024Applicant: CytoAgents, Inc.Inventor: Jodi Craigo
-
Patent number: 12042503Abstract: Compositions and methods that can be used to treat or prevent a viral infection are described herein. Prostacyclin/prostaglandin analogs can be used to treat infection by viruses such as SARS-CoV, MERS-CoV, and SARS-CoV-2. For example, pharmaceutical compositions containing beraprost or salts thereof can be used to treat infection by SARS-CoV-2 (the virus that causes the “COVID-19” disease).Type: GrantFiled: February 12, 2021Date of Patent: July 23, 2024Assignee: CytoAgents, Inc.Inventor: Jodi Craigo
-
Publication number: 20230381237Abstract: Methods, compositions, and kits that can be used to treat cytokine release syndrome, ICANS, or both, associated with CAR T-cell administration are described herein. For example, pharmaceutical compositions containing beraprost, beraprost isomers, or salts thereof can be used as an adjuvant therapy with chimeric antigen receptor T cells (CAR T-cells) to treat cancer while reducing or eliminating undesired and potentially dangerous side effects.Type: ApplicationFiled: May 30, 2023Publication date: November 30, 2023Applicant: CytoAgents, Inc.Inventors: Jodi CRAIGO, Teresa WHALEN, Heather Lynn NOTTINGHAM, Arthur P. BERTOLINO
-
Publication number: 20230242679Abstract: Compositions, methods, and kits that can be used to treat cancer, CRS, and ICANS are described herein. For example, pharmaceutical compositions containing beraprost, a beraprost isomer, or salts thereof can be used as an adjuvant therapy with bispecific antibodies to treat cancer while reducing or eliminating undesired and dangerous CRS effects.Type: ApplicationFiled: January 31, 2023Publication date: August 3, 2023Applicant: CytoAgents, Inc.Inventors: Jodi CRAIGO, Todd J. LORENZ, Arthur P. BERTOLINO
-
Publication number: 20220168352Abstract: Compositions, methods, and kits that can be used to treat cancer are described herein. For example, pharmaceutical compositions containing beraprost or salts thereof can be used as an adjuvant therapy with chimeric antigen receptor T-cells (CAR T-cells) to treat cancer while reducing or eliminating undesired and potentially dangerous cytokine release syndrome (CRS) effects.Type: ApplicationFiled: November 30, 2021Publication date: June 2, 2022Applicant: CytoAgents, Inc.Inventor: Jodi Craigo
-
Publication number: 20210244746Abstract: Compositions and methods that can be used to treat or prevent a viral infection are described herein. Prostacyclin/prostaglandin analogs can be used to treat infection by viruses such as SARS-CoV, MERS-CoV, and SARS-CoV-2. For example, pharmaceutical compositions containing beraprost or salts thereof can be used to treat infection by SARS-CoV-2 (the virus that causes the “COVID-19” disease).Type: ApplicationFiled: February 12, 2021Publication date: August 12, 2021Inventor: Jodi Craigo
-
Publication number: 20040219166Abstract: The invention provides an equine infectious anemia (EIA) vaccine and/or construct that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which, in embodiments, allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. In various embodiments, said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.Type: ApplicationFiled: July 24, 2003Publication date: November 4, 2004Inventors: Ronald C. Montelaro, Jodi Craigo, Feng Li
-
Patent number: 6727078Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test wich measures p26.Type: GrantFiled: April 18, 2002Date of Patent: April 27, 2004Assignees: Akzo Nobel N.V., University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessey, Karen K. Brown
-
Publication number: 20030026814Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease.Type: ApplicationFiled: April 18, 2002Publication date: February 6, 2003Inventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessey, Karen K. Brown
-
Publication number: 20030021807Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease.Type: ApplicationFiled: June 24, 2002Publication date: January 30, 2003Inventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessy, Karen K. Brown
-
Publication number: 20020155130Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Said composition allows differentiation between vaccinated and non-vaccinated, but exposed, mammals and provides safety and immunity when administered as a vaccine to mammals. Preferably said composition encompasses at least one deletion in a lentivirus which allows mammals to be safely vaccinated and provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals and, potentially, protection from infection from a foreign disease.Type: ApplicationFiled: April 18, 2002Publication date: October 24, 2002Inventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessey, Karen K. Brown
-
Patent number: 6461616Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test which measures p26.Type: GrantFiled: September 9, 2000Date of Patent: October 8, 2002Assignee: Akzo Nobel NVInventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessy, Karen K Brown